Indometacin farnesil

From Self-sufficiency
Jump to: navigation, search
Indometacin farnesil
Systematic (IUPAC) name
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
Clinical data
Routes of
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Metabolism To indometacin
Biological half-life 1.5 hours
Excretion Renal
CAS Number 85801-02-1
PubChem CID 5282183
Chemical data
Formula C34H40ClNO4
Molar mass 562.14 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.

External links


vi:Indomethacin farnesil